MSCs: Delivery routes and engraftment, cell-targeting strategies, and immune modulation

Stem Cells International

Volumn , Issue , 2013, Pages

  Kean, Thomas J ^a   Lin, Paul ^b   Caplan, Arnold I ^b   Dennis, James E ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; BISPECIFIC ANTIBODY; CXCL16 CHEMOKINE; CXCL9 CHEMOKINE; DNA; INDOLEAMINE 2,3 DIOXYGENASE; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; JAGGED1; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCYTE CHEMOTACTIC PROTEIN 3; NITRIC OXIDE; NOTCH RECEPTOR; PROSTAGLANDIN E2; PROTEIN A; PROTEIN ANTIBODY; PROTEIN G; RNA; SCATTER FACTOR; SELECTIN; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR STIMULATED GENE 6 PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1 ANTIBODY;

ANTIBODY DIRECTED CELL THERAPY; ANTIGEN EXPRESSION; CELL ADHESION; CELL DIFFERENTIATION; CELL EXPANSION; CELL INTERACTION; CELL SURFACE; CELL THERAPY; CELL TRANSFER; CHEMICAL MODIFICATION; DNA MODIFICATION; ENGRAFTMENT; GENETICALLY DIRECTED CELL THERAPY; HUMAN; IMMUNOMODULATION; INHIBITION KINETICS; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MIXED LYMPHOCYTE REACTION; NONHUMAN; PEPTIDE DIRECTED CELL THERAPY; PERICYTE; PRIORITY JOURNAL; PROTEIN SECRETION; RECEPTOR DOWN REGULATION; REVIEW; SELECTIN DIRECTED CELL THERAPY; T LYMPHOCYTE; TARGET CELL; TISSUE REGENERATION; TISSUE REPAIR;

EID: 84884274645     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2013/732742     Document Type: Review

References (138)

1. Caplan A. I., Mesenchymal stem cells. Journal of Orthopaedic Research 1991 9 5 641 650 2-s2.0-0026228558
2. Friedenstein A. J., Precursor cells of mechanocytes. International Review of Cytology 1976 47 327 359 2-s2.0-0017103248
3. Dennis J. E., Merriam A., Awadallah A., Yoo J. U., Johnstone B., Caplan A. I., A quadripotential mesenchymal progenitor cell isolated from the marrow of an adult mouse. Journal of Bone and Mineral Research 1999 14 5 700 709 2-s2.0-0032898767 10.1359/jbmr.1999.14.5.700
4. Vilquin J.-T., Rosset P., Mesenchymal stem cells in bone and cartilage repair: current status. Regenerative Medicine 2006 1 4 589 604 2-s2.0-33847742234 10.2217/17460751.1.4.589
5. Veronesi F., Giavaresi G., Tschon M., Borsari V., Nicoli Aldini N., Fini M., Clinical use of bone marrow, bone marrow concentrate, and expanded bone marrow mesenchymal stem cells in cartilage disease. Stem Cells and Development 2013 22 181 192
6. Caplan A. I., Dennis J. E., Mesenchymal stem cells as trophic mediators. Journal of Cellular Biochemistry 2006 98 5 1076 1084 2-s2.0-33746424373 10.1002/jcb.20886
7. Aksu A. E., Horibe E., Sacks J., Ikeguchi R., Breitinger J., Scozio M., Unadkat J., Feili-Hariri M., Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clinical Immunology 2008 127 3 348 358 2-s2.0-45249100402 10.1016/j.clim.2008.02.003
8. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M. E., Remberger M., Dini G., Egeler R. M., Bacigalupo A., Fibbe W., Ringdén O., Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. The Lancet 2008 371 9624 1579 1586 2-s2.0-43049103438 10.1016/S0140-6736(08)60690-X
9. Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A. I., Zhao R. C., Shi Y., Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008 2 2 141 150 2-s2.0-38649105374 10.1016/j.stem.2007.11.014
10. Bai L., Lennon D. P., Eaton V., Maier K., Caplan A. I., Miller S. D., Miller R. H., Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. GLIA 2009 57 11 1192 1203 2-s2.0-65649113921 10.1002/glia.20841
11. Connick P., Kolappan M., Crawley C., Webber D. J., Patani R., Michell A. W., Du M.-Q., Luan S.-L., Altmann D. R., Thompson A. J., Compston A., Scott M. A., Miller D. H., Chandran S., Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. The Lancet Neurology 2012 11 2 150 156 2-s2.0-84855982886 10.1016/S1474-4422(11)70305-2
12. Millard S. M., Fisk N. M., Mesenchymal stem cells for systemic therapy: shotgun approach or magic bullets? Bioessays 2013 35 173 182
13. Caplan A. I., Correa D., The MSC: an injury drugstore. Cell Stem Cell 2011 9 1 11 15 2-s2.0-79959951133 10.1016/j.stem.2011.06.008
14. Gonzalez-Rey E., Gonzalez M. A., Varela N., O'Valle F., Hernandez-Cortes P., Rico L., Büscher D., Delgado M., Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Annals of the Rheumatic Diseases 2010 69 1 241 248 2-s2.0-73449133395 10.1136/ard.2008.101881
15. Mueller M. B., Tuan R. S., Functional characterization of hypertrophy in chondrogenesis of human mesenchymal stem cells. Arthritis and Rheumatism 2008 58 5 1377 1388 2-s2.0-43949115205 10.1002/art.23370
16. Gerdoni E., Gallo B., Casazza S., Musio S., Bonanni I., Pedemonte E., Mantegazza R., Frassoni F., Mancardi G., Pedotti R., Uccelli A., Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Annals of Neurology 2007 61 3 219 227 2-s2.0-34147126415 10.1002/ana.21076
17. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., Uccelli A., Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005 106 5 1755 1761 2-s2.0-23944519424 10.1182/blood-2005-04-1496
18. Abdi R., Fiorina P., Adra C. N., Atkinson M., Sayegh M. H., Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008 57 7 1759 1767 2-s2.0-48249144864 10.2337/db08-0180
19. Urbán V. S., Kiss J., Kovács J., Gócza E., Vas V., Monostori E., Uher F., Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells 2008 26 1 244 253 2-s2.0-38349062691 10.1634/stemcells.2007-0267
20. García-Olmo D., García-Arranz M., Gómez García L., Cuellar E. S., Blanco I. F., Prianes L. A., Rodríguez Montes J. A., Pinto F. L., Marcos D. H., García-Sancho L., Autologous stem cell transplantation for treatment of rectovaginal fistula in perinatal Crohn's disease: a new cell-based therapy. International Journal of Colorectal Disease 2003 18 5 451 454 2-s2.0-10744233679 10.1007/s00384-003-0490-3
21. Gonzalez-Rey E., Anderson P., González M. A., Rico L., Büscher D., Delgado M., Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009 58 7 929 939 2-s2.0-60449093316 10.1136/gut.2008.168534
22. Hayashi Y., Tsuji S., Tsujii M., Nishida T., Ishii S., Iijima H., Nakamura T., Eguchi H., Miyoshi E., Hayashi N., Kawano S., Topical implantation of mesenchymal stem cells has beneficial effects on healing of experimental colitis in rats. Journal of Pharmacology and Experimental Therapeutics 2008 326 2 523 531 2-s2.0-47949120741 10.1124/jpet.108.137083
23. Yabana T., Arimura Y., Tanaka H., Goto A., Hosokawa M., Nagaishi K., Yamashita K., Yamamoto H., Adachi Y., Sasaki Y., Isobe M., Fujimiya M., Imai K., Shinomura Y., Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrity. Journal of Pathology 2009 218 3 350 359 2-s2.0-67650093720 10.1002/path.2535
24. Zhang X., Jiao C., Zhao S., Role of mesenchymal stem cells in immunological rejection of organ transplantation. Stem Cell Reviews and Reports 2010 5 4 402 409 2-s2.0-74649085434 10.1007/s12015-009-9076-y
25. Karp J. M., Leng Teo G. S., Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009 4 3 206 216 2-s2.0-60849136593 10.1016/j.stem.2009.02.001
26. Lin P., Lin Y., Lennon D. P., Correa D., Schluchter M., Caplan A. I., Efficient lentiviral transduction of human mesenchymal stem cells that preserves proliferation and differentiation capabilities. Stem Cells Translational Medicine 2012 1 886 897
27. Gao J., Dennis J. E., Muzic R. F., Lundberg M., Caplan A. I., The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001 169 1 12 20 2-s2.0-0035010796 10.1159/000047856
28. Srinivas M., Aarntzen E. H. J. G., Bulte J. W. M., Oyen W. J., Heerschap A., de Vries I. J. M., Figdor C. G., Imaging of cellular therapies. Advanced Drug Delivery Reviews 2010 62 11 1080 1093 2-s2.0-78649334161 10.1016/j.addr.2010.08.009
29. Reagan M. R., Kaplan D. L., Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells 2011 29 6 920 927 2-s2.0-79957617918 10.1002/stem.645
30. Kostura L., Kraitchman D. L., Mackay A. M., Pittenger M. F., Bulte J. M. W., Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis. NMR in Biomedicine 2004 17 7 513 517 2-s2.0-9244233296 10.1002/nbm.925
31. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringdén O., HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Experimental Hematology 2003 31 10 890 896 2-s2.0-0141484485 10.1016/S0301-472X(03)00110-3
32. Maitra B., Szekely E., Gjini K., Laughlin M. J., Dennis J., Haynesworth S. E., Koç O. N., Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplantation 2004 33 6 597 604 2-s2.0-1842483153 10.1038/sj.bmt.1704400
33. Tse W. T., Pendleton J. D., Beyer W. M., Egalka M. C., Guinan E. C., Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003 75 3 389 397 2-s2.0-0037442264 10.1097/01.TP.0000045055.63901.A9
34. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A., Hoffman R., Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental Hematology 2002 30 1 42 48 2-s2.0-0036142769 10.1016/S0301-472X(01)00769-X
35. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., Santarlasci V., Mazzinghi B., Pizzolo G., Vinante F., Romagnani P., Maggi E., Romagnani S., Annunziato F., Role for interferon- γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006 24 2 386 398 2-s2.0-33746889097 10.1634/stemcells.2005-0008
36. English K., Barry F. P., Field-Corbett C. P., Mahon B. P., IFN- γ and TNF- α differentially regulate immunomodulation by murine mesenchymal stem cells. Immunology Letters 2007 110 2 91 100 2-s2.0-34249662219 10.1016/j.imlet.2007.04.001
37. Ryan J. M., Barry F., Murphy J. M., Mahon B. P., Interferon- γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clinical and Experimental Immunology 2007 149 2 353 363 2-s2.0-34447298069 10.1111/j.1365-2249.2007.03422.x
38. Lee R. H., Pulin A. A., Seo M. J., Kota D. J., Ylostalo J., Larson B. L., Semprun-Prieto L., Delafontaine P., Prockop D. J., Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009 5 1 54 63 2-s2.0-67649171661 10.1016/j.stem.2009.05.003
39. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P. D., Matteucci P., Grisanti S., Gianni A. M., Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002 99 10 3838 3843 2-s2.0-0037093058 10.1182/blood.V99.10.3838
40. Cui L., Shuo Y., Liu W., Li N., Zhang W., Cao Y., Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Engineering 2007 13 6 1185 1195 2-s2.0-34250869446 10.1089/ten.2006.0315
41. Ren G., Su J., Zhang L., Zhao X., Ling W., L'Huillie A., Zhang J., Lu Y., Roberts A. I., Ji W., Zhang H., Rabson A. B., Shi Y., Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009 27 8 1954 1962 2-s2.0-69249119079 10.1002/stem.118
42. English K., Mechanisms of mesenchymal stromal cell immunomodulation. Immunology and Cell Biology 2013 91 19 26
43. Liotta F., Angeli R., Cosmi L., Filì L., Manuelli C., Frosali F., Mazzinghi B., Maggi L., Pasini A., Lisi V., Santarlasci V., Consoloni L., Angelotti M. L., Romagnani P., Parronchi P., Krampera M., Maggi E., Romagnani S., Annunziato F., Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing notch signaling. Stem Cells 2008 26 1 279 289 2-s2.0-38349060182 10.1634/stemcells.2007-0454
44. Brown S. L., Riehl T. E., Walker M. R., Geske M. J., Doherty J. M., Stenson W. F., Stappenbeck T. S., Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. Journal of Clinical Investigation 2007 117 1 258 269 2-s2.0-33846017279 10.1172/JCI29159
45. Li Y.-P., Paczesny S., Lauret E., Poirault S., Bordigoni P., Mekhloufi F., Hequet O., Bertrand Y., Ou-Yang J.-P., Stoltz J.-F., Miossec P., Eljaafari A., Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the notch pathway. Journal of Immunology 2008 180 3 1598 1608 2-s2.0-40749110247
46. Zhang B., Liu R., Shi D., Liu X., Chen Y., Dou X., Zhu X., Lu C., Liang W., Liao L., Zenke M., Zhao R. C. H., Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2 dependent regulatory dendritic cell population. Blood 2009 113 1 46 57 2-s2.0-59449096601 10.1182/blood-2008-04- 154138
47. Roddy G. W., Oh J. Y., Lee R. H., Bartosh T. J., Ylostalo J., Coble K., Rosa R. H. Jr., Prockop D. J., Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF- α stimulated gene/protein 6. Stem Cells 2011 29 10 1572 1579 2-s2.0-80053284296 10.1002/stem.708
48. Choi H., Lee R. H., Bazhanov N., Oh J. Y., Prockop D. J., Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF- B signaling in resident macrophages. Blood 2011 118 2 330 338 2-s2.0-79960464308 10.1182/blood-2010-12- 327353
49. Griffin M. D., Ryan A. E., Alagesan S., Lohan P., Treacy O., Ritter T., Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunology and Cell Biology 2013 91 40 51
50. Kotobuki N., Katsube Y., Katou Y., Tadokoro M., Hirose M., Ohgushi H., In vivo survival and osteogenic differentiation of allogeneic rat bone marrow mesenchymal stem cells (MSCs). Cell Transplantation 2008 17 6 705 712 2-s2.0-53749098532 10.3727/096368908786092793
51. Huang X.-P., Sun Z., Miyagi Y., Kinkaid H. M., Zhang L., Weisel R. D., Li R.-K., Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010 122 23 2419 2429 2-s2.0-78650686250 10.1161/CIRCULATIONAHA.110. 955971
52. Li Y., Lin F., Mesenchymal stem cells are injured by complement after their contact with serum. Blood 2012 120 3436 3443
53. von Bahr L., Batsis I., Moll G., Hagg M., Szakos A., Sundberg B., Uzunel M., Ringden O., Le Blanc K., Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012 30 1575 1578
54. Meyer G. P., Wollert K. C., Lotz J., Pirr J., Rager U., Lippolt P., Hahn A., Fichtner S., Schaefer A., Arseniev L., Ganser A., Drexler H., Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. European Heart Journal 2009 30 24 2978 2984 2-s2.0-72649085884 10.1093/eurheartj/ehp374
55. Abedin M., Tintut Y., Demer L. L., Mesenchymal stem cells and the artery wall. Circulation Research 2004 95 7 671 676 2-s2.0-4944232950 10.1161/01.RES.0000143421.27684.12
56. Crisan M., Yap S., Casteilla L., Chen C.-W., Corselli M., Park T. S., Andriolo G., Sun B., Zheng B., Zhang L., Norotte C., Teng P.-N., Traas J., Schugar R., Deasy B. M., Badylak S., Buhring H.-J., Giacobino J.-P., Lazzari L., Huard J., Péault B., A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008 3 3 301 313 2-s2.0-50849139576 10.1016/j.stem.2008.07.003
57. Shi S., Gronthos S., Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. Journal of Bone and Mineral Research 2003 18 4 696 704 2-s2.0-0042306316
58. Kang S.-G., Shinojima N., Hossain A., Gumin J., Yong R. L., Colman H., Marini F., Andreeff M., Lang F. F., Isolation and perivascular localization of mesenchymal stem cells from mouse brain. Neurosurgery 2010 67 3 711 720 2-s2.0-77956183605 10.1227/01.NEU.0000377859.06219.78
59. Zebardast N., Lickorish D., Davies J. E., Human umbilical cord perivascular cells (HUCPVC): a mesenchymal cell source for dermal wound healing. Organogenesis 2010 6 4 197 203 2-s2.0-77956420291 10.4161/org.6.4.12393
60. Cai X., Lin Y., Hauschka P. V., Grottkau B. E., Adipose stem cells originate from perivascular cells. Biology of the Cell 2011 103 9 435 447 2-s2.0-80955136605 10.1042/BC20110033
61. James A. W., Zara J. N., Corselli M., Askarinam A., Zhou A. M., Hourfar A., Nguyen A., Megerdichian S., Asatrian G., Pang S., Stoker D., Zhang X., Wu B., Ting K., Peault B., Soo C., An abundant perivascular source of stem cells for bone tissue engineering. Stem Cells Translational Medicine 2012 1 673 684
62. Gerlach J. C., Over P., Turner M. E., Thompson R. L., Foka H. G., Chen W. C., Peault B., Gridelli B., Schmelzer E., Perivascular mesenchymal progenitors in human fetal and adult liver. Stem Cells and Development 2012 21 3258 3269
63. Gronthos S., Brahim J., Li W., Fisher L. W., Cherman N., Boyde A., DenBesten P., Robey P. G., Shi S., Stem cell properties of human dental pulp stem cells. Journal of Dental Research 2002 81 8 531 535 2-s2.0-0036704390
64. Bianco P., Robey P. G., Simmons P. J., Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008 2 4 313 319 2-s2.0-41549139755 10.1016/j.stem.2008.03.002
65. Dore-Duffy P., Owen C., Balabanov R., Murphy S., Beaumont T., Rafols J. A., Pericyte migration from the vascular wall in response to traumatic brain injury. Microvascular Research 2000 60 1 55 69 2-s2.0-0033944791 10.1006/mvre.2000.2244
66. Maloney M. A., Lamela R. A., Patt H. M., The question of bone marrow stromal fibroblast traffic. Annals of the New York Academy of Sciences 1985 459 190 197 2-s2.0-0022271195
67. Kitaori T., Ito H., Schwarz E. M., Tsutsumi R., Yoshitomi H., Oishi S., Nakano M., Fujii N., Nagasawa T., Nakamura T., Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis and Rheumatism 2009 60 3 813 823 2-s2.0-61649090805 10.1002/art.24330
68. Schenk S., Mal N., Finan A., Zhang M., Kiedrowski M., Popovic Z., McCarthy P. M., Penn M. S., Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007 25 1 245 251 2-s2.0-33845992844 10.1634/stemcells.2006-0293
69. Chamberlain G., Smith H., Rainger G. E., Middleton J., Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: effects of chemokines and shear. PLoS ONE 2011 6 9 2-s2.0-80053269532 10.1371/journal.pone.0025663 e25663
70. Iwasaki M., Koyanagi M., Kossmann H., Monsefi N., Rupp S., Trauth J., Paulus P., Goetz R., Momma S., Tjwa M., Ohtani K., Henschler R., Schranz D., Cossu G., Zacharowski K., Martens S., Zeiher A. M., Dimmeler S., Hepatocyte growth factor mobilizes non-bone marrow-derived circulating mesoangioblasts. European Heart Journal 2011 32 5 627 636 2-s2.0-79952354882 10.1093/eurheartj/ ehq442
71. Kinnaird T., Burnett E. S., Shou M., Lee C. W., Barr S., Fuchs S., Epstein S. E., Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004 109 12 1543 1549 2-s2.0-1842486565 10.1161/01.CIR.0000124062.31102.57
72. Valarmathi M. T., Davis J. M., Yost M. J., Goodwin R. L., Potts J. D., A three-dimensional model of vasculogenesis. Biomaterials 2009 30 6 1098 1112 2-s2.0-57749181293 10.1016/j.biomaterials.2008.10.044
73. Arthur A., Zannettino A., Gronthos S., The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. Journal of Cellular Physiology 2009 218 2 237 245 2-s2.0-58149265734 10.1002/jcp.21592
74. Augello A., Tasso R., Negrini S. M., Cancedda R., Pennesi G., Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis and Rheumatism 2007 56 4 1175 1186 2-s2.0-34247231682 10.1002/art.22511
75. Caplan A. I., Osteogenesis imperfecta, rehabilitation medicine, fundamental research and mesenchymal stem cells. Connective Tissue Research 1995 31 4 S9 S14 2-s2.0-0002624625
76. Castelo-Branco M. T. L., Soares I. D. P., Lopes D. V., Buongusto F., Martinusso C. A., do Rosario A. Jr., Souza S. A. L., Gutfilen B., Fonseca L. M. B., Elia C., Madi K., Schanaider A., Rossi M. I. D., Souza H. S. P., Intraperitoneal but not intravenous cryopreserved mesenchymal stromal cells home to the inflamed colon and ameliorate experimental colitis. PLoS ONE 2012 7 3 2-s2.0-84858166198 10.1371/journal.pone.0033360 e33360
77. Tang Y., Shah K., Messerli S. M., Snyder E., Breakefield X., Weissleder R., In vivo tracking of neural progenitor cell migration to glioblastomas. Human Gene Therapy 2003 14 13 1247 1254 2-s2.0-0041882045 10.1089/104303403767740786
78. Wilson T., Stark C., Holmbom J., Rosling A., Kuusilehto A., Tirri T., Penttinen R., Ekholm E., Fate of bone marrow-derived stromal cells after intraperitoneal infusion or implantation into femoral bone defects in the host animal. Journal of Tissue Engineering 2010 2010 345806 10.4061/2010/345806
79. Dinh A. T., Kubis N., Tomita Y., Karaszewski B., Calando Y., Oudina K., Petite H., Seylaz J., Pinard E., In vivo imaging with cellular resolution of bone marrow cells transplanted into the ischemic brain of a mouse. NeuroImage 2006 31 3 958 967 2-s2.0-33744938906 10.1016/j.neuroimage.2006.01.019
80. Dvorak H. F., Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing. New England Journal of Medicine 1986 315 26 1650 1659 2-s2.0-0022891340
81. Nakamura K., Ito Y., Kawano Y., Kurozumi K., Kobune M., Tsuda H., Bizen A., Honmou O., Niitsu Y., Hamada H., Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Therapy 2004 11 14 1155 1164 2-s2.0-4243125420 10.1038/sj.gt.3302276
82. Chabner K. T., Adams G. B., Qiu J., Moskowitz M., Marsters E. S., Topulos G. P., Scadden D. T., Direct vascular delivery of primitive hematopoietic cells to bone marrow improves localization but not engraftment. Blood 2004 103 12 4685 4686 2-s2.0-2942616381 10.1182/blood-2003-12-4145
83. Fischer U. M., Harting M. T., Jimenez F., Monzon-Posadas W. O., Xue H., Savitz S. I., Laine G. A., Cox C. S., Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells and Development 2009 18 5 683 691 2-s2.0-66249096305 10.1089/scd.2008.0253
84. Sekiya I., Larson B. L., Smith J. R., Pochampally R., Cui J.-G., Prockop D. J., Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002 20 6 530 541 2-s2.0-0036456669
85. Schrepfer S., Deuse T., Reichenspurner H., Fischbein M. P., Robbins R. C., Pelletier M. P., Stem cell transplantation: the lung barrier. Transplantation Proceedings 2007 39 2 573 576 2-s2.0-33847701666 10.1016/j.transproceed.2006.12.019
86. Nystedt J., Anderson H., Tikkanen J., Pietila M., Hirvonen T., Takalo R., Heiskanen A., Satomaa T., Natunen S., Lehtonen S., Hakkarainen T., Korhonen M., Laitinen S., Valmu L., Lehenkari P., Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem Cells 2013 31 317 326
87. Horwitz E. M., Gordon P. L., Koo W. K. K., Marx J. C., Neel M. D., McNall R. Y., Muul L., Hofmann T., Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proceedings of the National Academy of Sciences of the United States of America 2002 99 13 8932 8937 2-s2.0-0037173116 10.1073/pnas.132252399
88. Horwitz E. M., Prockop D. J., Fitzpatrick L. A., Koo W. W. K., Gordon P. L., Neel M., Sussman M., Orchard P., Marx J. C., Pyeritz R. E., Brenner M. K., Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nature Medicine 1999 5 3 309 313 2-s2.0-0032976690 10.1038/6529
89. Fouillard L., Chapel A., Bories D., Bouchet S., Costa J.-M., Rouard H., Hervé P., Gourmelon P., Thierry D., Lopez M., Gorin N. C., Infusion of allogeneic-related HLA mismatched mesenchymal stem cells for the treatment of incomplete engraftment following autologous haematopoietic stem cell transplantation. Leukemia 2007 21 3 568 570 2-s2.0-33847177678 10.1038/sj.leu.2404550
90. Muller-Ehmsen J., The problem is obvious, the solution is not: numbers do matter in cardiac cell therapy! Cardiovascular Research 2012 96 208 209
91. Ankrum J., Karp J. M., Mesenchymal stem cell therapy: two steps forward, one step back. Trends in Molecular Medicine 2010 16 5 203 209 2-s2.0-77952319188 10.1016/j.molmed.2010.02.005
92. Le Blanc K., Rasmusson I., Sundberg B., Götherström C., Hassan M., Uzunel M., Ringdén O., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet 2004 363 9419 1439 1441 2-s2.0-2342482526 10.1016/S0140-6736(04)16104-7
93. Arguello F., Baggs R. B., Frantz C. N., A murine model of experimental metastasis to bone and bone marrow. Cancer Research 1988 48 23 6876 6881 2-s2.0-0024262906
94. Tögel F., Yang Y., Zhang P., Hu Z., Westenfelder C., Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. American Journal of Physiology 2008 295 1 F315 F321 2-s2.0-49949090094 10.1152/ajprenal.00098.2008
95. Tögel F., Hu Z., Weiss K., Isaac J., Lange C., Westenfelder C., Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. American Journal of Physiology 2005 289 1 F31 F42 2-s2.0-20844440562 10.1152/ajprenal.00007.2005
96. Walczak P., Zhang J., Gilad A. A., Kedziorek D. A., Ruiz-Cabello J., Young R. G., Pittenger M. F., Van Zijl P. C. M., Huang J., Bulte J. W. M., Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke 2008 39 5 1569 1574 2-s2.0-44449176192 10.1161/STROKEAHA.107.502047
97. Janowski M., Lyczek A., Engels C., Xu J., Lukomska B., Bulte J. W., Walczak P., Cell size and velocity of injection are major determinants of the safety of intracarotid stem cell transplantation. Journal of Cerebral Blood Flow and Metabolism 2013 33 921 927
98. Li L., Jiang Q., Ding G., Zhang L., Zhang Z. G., Li Q., Panda S., Lu M., Ewing J. R., Chopp M., Effects of administration route on migration and distribution of neural progenitor cells transplanted into rats with focal cerebral ischemia, an MRI study. Journal of Cerebral Blood Flow and Metabolism 2010 30 3 653 662 2-s2.0-77649271334 10.1038/jcbfm.2009.238
99. Kyriakou C., Rabin N., Pizzey A., Nathwani A., Yong K., Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model. Haematologica 2008 93 10 1457 1465 2-s2.0-54349101485 10.3324/haematol.12553
100. Fleck A., Raines G., Hawker F., Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. The Lancet 1985 1 8432 781 784 2-s2.0-0021963073
101. Brown L. F., Yeo K.-T., Berse B., Yeo T.-K., Senger D. R., Dvorak H. F., Van de Water L., Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. Journal of Experimental Medicine 1992 176 5 1375 1379 2-s2.0-0026756163 10.1084/jem.176.5.1375
102. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release 2000 65 1-2 271 284 2-s2.0-0034000453 10.1016/S0168-3659(99)00248-5
103. Prockop D. J., Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Molecular Therapy 2009 17 6 939 946 2-s2.0-67349204472 10.1038/mt.2009.62
104. Torchilin V. P., Multifunctional nanocarriers. Advanced Drug Delivery Reviews 2006 58 14 1532 1555 2-s2.0-34249820576 10.1016/j.addr.2006.09.009
105. Stephan M. T., Irvine D. J., Enhancing cell therapies from the outside in: cell surface engineering using synthetic nanomaterials. Nano Today 2011 6 3 309 325 2-s2.0-79958831612 10.1016/j.nantod.2011.04.001
106. Burnett A. K., Treatment of acute myeloid leukemia: are we making progress? Hematology/The Education Program of the American Society of Hematology 2012 2012 1 6 10.1182/asheducation-2012.1.1
107. Larson R. A., Boogaerts M., Estey E., Karanes C., Stadtmauer E. A., Sievers E. L., Mineur P., Bennett J. M., Berger M. S., Eten C. B., Munteanu M., Loken M. R., van Dongen J. J. M., Bernstein I. D., Appelbaum F. R., Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002 16 9 1627 1636 2-s2.0-0036733277 10.1038/sj.leu.2402677
108. Verma S., Miles D., Gianni L., Krop I. E., Welslau M., Baselga J., Pegram M., Oh D. Y., Dieras V., Guardino E., Fang L., Lu M. W., Olsen S., Blackwell K., Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine 2012 367 1783 1791
109. Ko I. K., Kean T. J., Dennis J. E., Targeting mesenchymal stem cells to activated endothelial cells. Biomaterials 2009 30 22 3702 3710 2-s2.0-67349104874 10.1016/j.biomaterials.2009.03.038
110. Ko I. K., Kim B.-G., Awadallah A., Mikulan J., Lin P., Letterio J. J., Dennis J. E., Targeting improves MSC treatment of inflammatory bowel disease. Molecular Therapy 2010 18 7 1365 1372 2-s2.0-77954242073 10.1038/mt.2010.54
111. Dennis J. E., Cohen N., Goldberg V. M., Caplan A. I., Targeted delivery of progenitor cells for cartilage repair. Journal of Orthopaedic Research 2004 22 4 735 741 2-s2.0-2942596445 10.1016/j.orthres.2003.12.002
112. Lee R. J., Fang Q., Davol P. A., Gu Y., Sievers R. E., Grabert R. C., Gall J. M., Tsang E., Yee M. S., Fok H., Huang N. F., Padbury J. F., Larrick J. W., Lum L. G., Antibody targeting of stem cells to infarcted myocardium. Stem Cells 2007 25 3 712 717 2-s2.0-33847631364 10.1634/stemcells.2005-0602
113. Lum L. G., Fok H., Sievers R., Abedi M., Quesenberry P. J., Lee R. J., Targeting of Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardium. Blood Cells, Molecules, and Diseases 2004 32 1 82 87 2-s2.0-0742289570 10.1016/j.bcmd.2003.09.019
114. Zhao T. C., Tseng A., Yano N., Tseng Y., Davol P. A., Lee R. J., Lum L. G., Padbury J. F., Targeting human CD34+ hematopoietic stem cells with anti-CD45 X anti-myosin light-chain bispecific antibody preserves cardiac function in myocardial infarction. Journal of Applied Physiology 2008 104 6 1793 1800 2-s2.0-49649102917 10.1152/japplphysiol.01109.2007
115. Kim S. A., Peacock J. S., The use of palmitate-conjugated protein A for coating cells with artificial receptors which facilitate intercellular interactions. Journal of Immunological Methods 1993 158 1 57 65 2-s2.0-0027472480 10.1016/0022-1759(93)90258-9
116. Chen A., Zheng G., Tykocinski M. L., Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method. Journal of Immunology 2000 164 2 705 711 2-s2.0-0034650809
117. Sen M., Wankowski D. M., Garlie N. K., Siebenlistd R. E., Van Epps D., LeFever A. V., Lum L. G., Use of anti-CD3 × anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. Journal of Hematotherapy and Stem Cell Research 2001 10 2 247 260 2-s2.0-0034744176 10.1089/15258160151134944
118. Chan J. K., Hamilton C. A., Cheung M. K., Karimi M., Baker J., Gall J. M., Schulz S., Thorne S. H., Teng N. N., Contag C. H., Lum L. G., Negrin R. S., Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clinical Cancer Research 2006 12 6 1859 1867 2-s2.0-33645690747 10.1158/1078-0432.CCR-05-2019
119. Gundlach C. W. IV, Caivano A., Da Graca Cabreira-Hansen M., Gahremanpour A., Brown W. S., Zheng Y., McIntyre B. W., Willerson J. T., Dixon R. A. F., Perin E. C., Woodside D. G., Synthesis and evaluation of an anti-MLC1 × anti-CD90 bispecific antibody for targeting and retaining bone-marrow-derived multipotent stromal cells in infarcted myocardium. Bioconjugate Chemistry 2011 22 8 1706 1714 2-s2.0-80051739082 10.1021/bc200309h
120. Doppalapudi V. R., Huang J., Liu D., Jin P., Liu B., Li N., Desharnais J., Hagen C., Levin N. J., Shields M. J., Parish M., Murphy R. E., Del Rosario J., Oates B. D., Lai J.-Y., Matin M. J., Ainekulu Z., Bhat A., Bradshaw C. W., Woodnutt G., Lerner R. A., Lappe R. W., Chemical generation of bispecific antibodies. Proceedings of the National Academy of Sciences of the United States of America 2010 107 52 22611 22616 2-s2.0-78651091039 10.1073/pnas.1016478108
121. Cheng Z., Ou L., Zhou X., Li F., Jia X., Zhang Y., Liu X., Li Y., Ward C. A., Melo L. G., Kong D., Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Molecular Therapy 2008 16 3 571 579 2-s2.0-39849097361 10.1038/sj.mt.6300374
122. Zhang D., Fan G.-C., Zhou X., Zhao T., Pasha Z., Xu M., Zhu Y., Ashraf M., Wang Y., Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. Journal of Molecular and Cellular Cardiology 2008 44 2 281 292 2-s2.0-39149089319 10.1016/j.yjmcc.2007.11.010
123. Cho S. W., Sun H. J., Yang J.-Y., Jung J. Y., An J. H., Cho H. Y., Choi H. J., Kim S. W., Kim S. Y., Kim D., Shin C. S., Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice. Molecular Therapy 2009 17 11 1979 1987 2-s2.0-70449123822 10.1038/mt.2009.153
124. Lien C.-Y., Ho K. C.-Y., Lee O. K., Blunn G. W., Su Y., Restoration of bone mass and strength in glucocorticoid-treated mice by systemic transplantation of CXCR4 and Cbfa-1 co-expressing mesenchymal stem cells. Journal of Bone and Mineral Research 2009 24 5 837 848 2-s2.0-65949116788 10.1359/jbmr.081257
125. Kochenderfer J. N., Wilson W. H., Janik J. E., Dudley M. E., Stetler-Stevenson M., Feldman S. A., Maric I., Raffeld M., Nathan D.-A. N., Lanier B. J., Morgan R. A., Rosenberg S. A., Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010 116 20 4099 4102 2-s2.0-78549278144 10.1182/blood-2010-04-281931
126. Park T. S., Rosenberg S. A., Morgan R. A., Treating cancer with genetically engineered T cells. Trends in Biotechnology 2011 29 11 550 557 2-s2.0-80054680991 10.1016/j.tibtech.2011.04.009
127. Xia L., McDaniel J. M., Yago T., Doeden A., McEver R. P., Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood 2004 104 10 3091 3096 2-s2.0-8644254413 10.1182/blood-2004-02-0650
128. Sackstein R., Merzaban J. S., Cain D. W., Dagia N. M., Spencer J. A., Lin C. P., Wohlgemuth R., Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nature Medicine 2008 14 2 181 187 2-s2.0-38949183635 10.1038/nm1703
129. Aplin A. E., Howe A., Alahari S. K., Juliano R. L., Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacological Reviews 1998 50 2 197 263 2-s2.0-0031745571
130. Sarkar D., Vemula P. K., Teo G. S. L., Spelke D., Karnik R., Wee L. Y., Karp J. M., Chemical engineering of mesenchymal stem cells to induce a cell rolling response. Bioconjugate Chemistry 2008 19 11 2105 2109 2-s2.0-56749095472 10.1021/bc800345q
131. Sarkar D., Spencer J. A., Phillips J. A., Zhao W., Schafer S., Spelke D. P., Mortensen L. J., Ruiz J. P., Vemula P. K., Sridharan R., Kumar S., Karnik R., Lin C. P., Karp J. M., Engineered cell homing. Blood 2011 118 25 e184 e191 2-s2.0-84055223060 10.1182/blood-2010-10-311464
132. Sarkar D., Vemula P. K., Zhao W., Gupta A., Karnik R., Karp J. M., Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting. Biomaterials 2010 31 19 5266 5274 2-s2.0-77952287644 10.1016/j.biomaterials.2010.03.006
133. Crockett-Torabi E., Selectins and mechanisms of signal transduction. Journal of Leukocyte Biology 1998 63 1 1 14 2-s2.0-0031940687
134. Shadidi M., Sioud M., Selective targeting of cancer cells using synthetic peptides. Drug Resistance Updates 2003 6 6 363 371 2-s2.0-0842312445 10.1016/j.drup.2003.11.002
135. Ruoslahti E., Vascular zip codes in angiogenesis and metastasis. Biochemical Society Transactions 2004 32 3 397 402 2-s2.0-3042660212 10.1042/BST0320397
136. Ruoslahti E., Bhatia S. N., Sailor M. J., Targeting of drugs and nanoparticles to tumors. Journal of Cell Biology 2010 188 6 759 768 2-s2.0-77949762340 10.1083/jcb.200910104
137. Kean T. J., Duesler L., Young R. G., Dadabayev A., Olenyik A., Penn M., Wagner J., Fink D. J., Caplan A. I., Dennis J. E., Development of a peptide-targeted, myocardial ischemia-homing, mesenchymal stem cell. Journal of Drug Targeting 2012 20 1 23 32 2-s2.0-83155191797 10.3109/1061186X.2011.622398
138. Majumdar S., Siahaan T. J., Peptide-mediated targeted drug delivery. Medicinal Research Reviews 2012 32 3 637 658 2-s2.0-84860317690 10.1002/med.20225